By using in vitro studies, the authors further demonstrated that patient-derived senescent-like T cells were not able to sufficiently eliminate autologous AML blasts compared with their nonsenescent CD8+ T-cell counterparts, providing direct evidence for their limited antileukemic activity (55). This evidence concerns the gene CD8A and acute myeloid leukemia.